Mafalda C Ramos (Mafalda Ramos)

Years Active: 2019-2021
Publications (10 Years): 5

IQVIA

Universitat Pompeu Fabra (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

IQVIA

Belgium

Senior Consultant :: HEOR, RWE

Education History

Universitat Pompeu Fabra

Spain

MSC :: Barcelona School of Management

Publications

Mafalda C Ramos, Peng Men, Xu Wang, Anastasia Ustyugova, Mark Lamotte
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost effectiveness and resource allocation : C/E 19 (1) (2021)
Lars Holger Ehlers, Mark Lamotte, Mafalda C Ramos, Susanne Sandgaard, Pia Holmgaard, Evan C Frary, Niels Ejskjær
The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. Journal of comparative effectiveness research 11 (1) (2021)
Ahmed Salem, Peng Men, Mafalda C Ramos, Yan-Jun Zhang, Anastasia Ustyugova, Mark Lamotte
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of comparative effectiveness research 10 (6) (2021)
Mafalda C Ramos, Anastasia Ustyugova, Nikco Hau, Mark Lamotte
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. Journal of comparative effectiveness research 9 (11) (2020)
Mafalda C Ramos, Volker Foos, Anastasia Ustyugova, Nikco Hau, Pranav Gandhi, Mark Lamotte
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes therapy : research, treatment and education of diabetes and related disorders 10 (6) (2019)

Mafalda C Ramos.css-eqlu8i{font-size:small;padding-left:4px;} (Mafalda Ramos)